Stock Financial Ratios


MOH / Molina Healthcare, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price93.77
Volume1,637,800.00
Market Cap ($M)5,108.91
Enterprise Value ($M)2,044.56
Book Value ($M)1,649.00
Book Value / Share29.45
Price / Book3.58
NCAV ($M)2,879.00
NCAV / Share51.41
Price / NCAV1.56
Income Statement (mra) ($M)
Revenue17,782.00
EBITDA306.00
Net Income52.00
Balance Sheet (mrq) ($M)
Cash & Equivalents3,934.00
Cash / Share70.25
Assets8,628.00
Liabilities7,525.00
Quick Ratio1.31
Current Ratio1.31
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.01
Return on Assets (ROA)0.01
Return on Equity (ROE)0.03
Identifiers and Descriptors
CUSIP60855R100
Central Index Key (CIK)1179929
Industry Groups
SIC 6324 - Hospital and Medical Service Plans
Other Related CUSIPS
60855R900
60855R950
Share Statistics
Common Shares Outstanding (M)57.09
Scoring Models
Piotroski F Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Per Share154.07
Assets Other Non Current Per Share0.75
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Additional Paid In Capital Per Share15.54
Liabilities And Stock Equity Per Share159.89
Liabilities Other Non Current Per Share0.86
Property Plant And Equipment Net Per Share7.09
Goodwill Per Share7.68
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Per Share134.38
Preferred Stock Value Outstanding Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Property Plant And Equipment Per Share7.09
Retained Earnings Per Share10.00
Assets Current Per Share131.82
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Long Term Debt Per Share23.52
Inventory Raw Materials Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Cash Per Share70.25
Assets Non Current Per Share0.00
Inventory Per Share0.00
Debt Per Share27.05
Cash And Equivalents Per Share70.25
Liabilities Current Per Share106.46
Intangibles Per Share0.00
Equity Per Share25.52
Inventory Work In Progress Per Share0.00

Related News Stories

CVS Health Grows on Pharmacy Services, Retail Remains a Drag

2018-01-16 zacks
On Jan 12, we issued an updated research report on CVS Health (CVS - Free Report) . The company carries a Zacks Rank #3 (Hold). (37-0)

Boston Scientific's Positive SCS Trial Aids Neuromodulation

2018-01-16 zacks
Boston Scientific Corporation’s (BSX - Free Report) successful result from its WHISPER randomized controlled trial (RCT) further boosts its neuromodulation business. This announcement follows the recent FDA approval of Spectra WaveWriter Spinal Cord Stimulator System (SCS) within the neuromodulation arm. (102-0)

IDEXX Launches Catalyst SDMA for Veterinary Renal Disorder

2018-01-15 zacks
IDEXX Laboratories, Inc. (IDXX - Free Report) has announced the commercial launch of its Catalyst SDMA Test to all North American customers, scheduled on Jan 16, 2018. With this, IDEXX’s point-of-care customers will now be able to add SDMA as an essential element to the routine chemistry panel. (52-0)

Boston Scientific Fortifies Pain Therapy Arm With FDA Nod

2018-01-15 zacks
Boston Scientific (BSX - Free Report) is hitting headlines with successive new developments, the latest feat being the company’s Spectra WaveWriter Spinal Cord Stimulator System (SCS) getting an FDA nod. Per Boston Scientific, this is the only FDA-approved SCS system to provide paresthesia-based and sub-perception therapies. (83-0)

5 HMO Stocks to Continue Rewarding Investors

2018-01-12 zacks
The Health Maintenance Organization (HMO) industry has consistently outperformed the S&P 500 over the last five years with its 285.2% appreciation, easily trumping the S&P 500’s 90.2%.  But the industry started pulling even further ahead in 2015 and again after the election of President Donald Trump. It is currently in the top 9% of Zacks industries. (72-1)

CUSIP: 60855R100